







L Number	Hits	Search Text	DB	Time stamp
1	206	((544/254) or (514/261.1)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/12 16:23



chain nodes :

45 47

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 23 24 25 26 27 28
29 30 31 32 33 34 35 36 37 38 39 40

chain bonds :

45-47

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-15 12-13 13-14 14-15 16-17
16-20 17-18 18-19 19-20 23-24 23-28 24-25 24-29 25-26 25-31 26-27 27-28 29-30
30-31 32-33 32-37 33-34 33-38 34-35 34-40 35-36 36-37 38-39 39-40

exact/norm bonds :

2-3 2-7 3-9 7-8 8-9 12-13 13-14 17-18 18-19 24-25 24-29 25-31 29-30 30-31
33-34 33-38 34-40 38-39 39-40 45-47

exact bonds :

11-12 11-15 14-15 16-17 16-20 19-20

normalized bonds :

1-2 1-6 3-4 4-5 5-6 23-24 23-28 25-26 26-27 27-28 32-33 32-37 34-35 35-36
36-37

isolated ring systems :

containing 1 : 11 : 16 : 23 : 32 :

G1:[*1],[*2],[*3]

G2:[*4],[*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom
35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 45:CLASS 47:CLASS

=>

Uploading 10070211.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:34:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4 TO 200

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 13:34:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 84 TO ITERATE

100.0% PROCESSED 84 ITERATIONS

17 ANSWERS

SEARCH TIME: 00.00.01

L3 17 SEA SSS FUL L1

=> s l3

L4 1 L3

=> d bib,ab,hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:208275 CAPLUS
 DN 134:237500
 TI Preparation of triazolo-pyrimidinyl-pyrrolidinol derivatives as receptor agonists, inhibitors of platelet activation, and antithrombotics
 IN Teobald, Barry John
 PA Astrazeneca UK Limited, UK
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019826	A2	20010322	WO 2000-GB3474	20000911
	WO 2001019826	A3	20011011		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1216248	A2	20020626	EP 2000-958857	20000911
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP	2003509426	T2	20030311	JP 2001-523403	20000911
PRAI	SE 1999-3290	A	19990915		
	WO 2000-GB3474	W	20000911		
OS	MARPAT 134:237500				
AB	<p>Triazolo-pyrimidinyl-pyrrolidinol derivs. I, wherein: R1 is H, CH2R5 or COR6; R2 is alkyl C1-6 or alkenyl C1-6, optionally substituted by one or more groups selected from alkyl C1-6, halogen; R3 is cycloalkyl C3-8, optionally substituted by R7; R4 is H or alkyl C1-6, optionally substituted by one or more halogens; R5 is H, Ph or alkyl C1-6, optionally substituted by halogen, OR8, phenyl; R6 is OR9 or alkyl C1-6, optionally substituted by one or more groups selected from halogen, OR10, phenyl; R7 is Ph, optionally substituted by one or more groups selected from alkyl C1-6, halogen, OR8; R8- R10, are independently H or alkyl C1-6, optionally substituted by one or more groups selected from halogen or alkyl C1-6; were prep'd. as antithrombotic agents. Thus, [3R-[3.alpha.,4.beta.(1R*,2S*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol was prep'd. as antithrombotic agent. The use of these compds. as an active ingredient in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischemic attacks, and/or peripheral vascular disease.</p>				
IT	<p>330681-16-8P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of triazolo-pyrimidinyl-pyrrolidinol derivs. as receptor agonists, inhibitors of platelet activation, and antithrombotics)</p>				
RN	330681-16-8	CAPLUS			
CN	3-Pyrrolidinol, 4-[7-[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-				


3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)-, trifluoroacetate
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330681-15-7

CMF C20 H25 N7 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 330681-15-7P 330681-22-6P 330681-24-8P
330681-25-9P 330681-26-0P 330681-27-1P
330681-29-3P 330681-30-6P 330681-32-8P
330681-33-9P 330681-34-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of triazolo-pyrimidinyl-pyrrolidinol derivs. as receptor agonists, inhibitors of platelet activation, and antithrombotics)

RN 330681-15-7 CAPLUS

CN 3-Pyrrolidinol, 4-[7-[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330681-22-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[7-[(1S,2R)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, 1,1-dimethylethyl ester, (3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330681-24-8 CAPLUS

CN 3-Pyrrolidinol, 4-[7-[(1S,2R)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330681-25-9 CAPLUS
 CN 3-Pyrrolidinol, 4-[7-[[(1S,2R)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3S,4S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 330681-24-8
 CMF C20 H25 N7 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 330681-26-0 CAPLUS
 CN 3-Pyrrolidinol, 4-[7-[methyl[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330681-27-1 CAPLUS


CN 3-Pyrrolidinol, 4-[7-[methyl[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330681-26-0

CMF C21 H27 N7 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 330681-29-3 CAPLUS

CN 1-Pyrrolidineethanol, 3-hydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 330681-30-6 CAPLUS


CN 1-Pyrrolidineethanol, 3-hydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330681-29-3

CMF C22 H29 N7 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 330681-32-8 CAPLUS

CN 3-Pyrrolidinol, 4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1-(phenylmethyl)-, (3R,4R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 330681-33-9 CAPLUS


CN 3-Pyrrolidinol, 4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1-(phenylmethyl)-, (3R,4R)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330681-32-8

CMF C27 H31 N7 O S

Absolute stereochemistry.




10/070,211

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 330681-34-0 CAPLUS

CN 3-Pyrrolidinol, 1-acetyl-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 330681-19-1P 330681-20-4P 330681-28-2P

330681-31-7P 330683-37-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of triazolo-pyrimidinyl-pyrrolidinol derivs. as receptor agonists, inhibitors of platelet activation, and antithrombotics)

RN 330681-19-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[7-chloro-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-4-hydroxy-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330681-20-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[7-[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330681-28-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[7-[methyl[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330681-31-7 CAPLUS

CN 3-Pyrrolidinol, 1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-4-[7-
[[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-
d]pyrimidin-3-yl]-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330683-37-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[7-chloro-5-(propylthio)-3H-1,2,3-
triazolo[4,5-d]pyrimidin-3-yl]-4-hydroxy-, 1,1-dimethylethyl ester,
(3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 13:33:21 ON 12 DEC 2003)

FILE 'REGISTRY' ENTERED AT 13:33:31 ON 12 DEC 2003

L1 STRUCTURE UPLOADED

L2 1 S L1 SSS SAM

L3 17 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 13:34:37 ON 12 DEC 2003

L4 1 S L3

FILE 'CAOLD' ENTERED AT 13:35:02 ON 12 DEC 2003

=> s l3

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.40

154.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-0.65

STN INTERNATIONAL LOGOFF AT 13:35:41 ON 12 DEC 2003